Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lucian de Waal"'
Autor:
Lucian de Waal, Kevin Larpenteur, Li Wang, Cong Zhu, Jordan Bryan, Mustafa Kocak, Corrie Aghia, Joshua Bittker, Victor Jones, Anita Vrcic, Edward McBride, Samantha Bender, Kalea Gore, Frank Li, Zhenghao Chen, Aviad Tsherniak, Aravind Subramanian, Daphne Koller, Jeffery Settleman, Chris C. Mader, David Stokoe, Ari Firestone, Jennifer A. Roth, Todd R. Golub
Publikováno v:
Cancer Research. 82:1883-1883
Oncology drug discovery has been dependent on phenotypic screening that lead to discovery of many drugs that remain essential cancer treatments to this day. Historically, logistical and technological limitations have hampered the scale of phenotypic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eefba6f86fb922145fd0b969300c0818
https://doi.org/10.1158/1538-7445.am2022-1883
https://doi.org/10.1158/1538-7445.am2022-1883
Autor:
James M. McFarland, Samantha Bender, David Stokoe, Lucian de Waal, Jordan Bryan, Ari J. Firestone, Colin Trepiccio, Federica Piccioni, David E. Root, Li Wang, Michael V. Rothberg, Kevin Larpenteur, Matt Kukurugya, Christopher C. Mader, Amy Goodale, Jennifer Roth, Bryson Bennett, Brenton R. Paolella, Sulyman Barkho, Josh Bittker, Min Cho, Aviad Tsherniak, Mustafa Kocak, Todd R. Golub, Cong Zhu, James Rong
Publikováno v:
Molecular Cancer Therapeutics. 18:C022-C022
A comprehensive analysis of FDA approved drugs has shown that drug discovery through phenotypic screening yields a higher percentage of first-in-class compounds, compared to canonical target-based drug discovery. This has led to a renewed interest in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::392c85747bde088091c15122237dea8b
https://doi.org/10.1158/1535-7163.targ-19-c022
https://doi.org/10.1158/1535-7163.targ-19-c022
Autor:
Patrick W. Faloon, Christina R. Hartigan, Matthew G. Rees, Alex B. Burgin, Stuart L. Schreiber, Lara Gechijian, Mark Hickey, Peter S. Choi, Alykhan F. Shamji, Paul A. Clemons, Lucian De Waal, Heidi Greulich, Xiaoyun Wu, Nicola Tolliday, Aviad Tsherniak, Timothy A. Lewis, Steven A. Carr, Bridget K. Wagner, Benito Munoz, Monica Schenone, Angela N. Koehler, Matthew Meyerson
Publikováno v:
Molecular Cancer Therapeutics. 14:C136-C136
High cancer death rates indicate the need for new anti-cancer therapeutic agents. Approaches to discover new cancer drugs include target-based drug discovery and phenotypic screening. Here, we identify phosphodiesterase 3A modulators as cell-selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56787771b172a2da30bf65c61467a100
https://doi.org/10.1158/1535-7163.targ-15-c136
https://doi.org/10.1158/1535-7163.targ-15-c136